Pharmaceutical composition containing high drug load and method for preparing same

• US 5,049,394 A
• Filed: 03/15/1989
• Issued: 09/17/1991
• Est. Priority Date: 09/11/1987
• Status: Expired due to Term

• Current Assignee: E R Squibb & Sons Incorporated
• Original Assignee: E R Squibb & Sons Incorporated
• Inventors: Howard, John R., Delargy, Anne M.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): SPEAR, JAMES M
• Application Number:
  US07/323,717
• Time in Patent Office: 916 Days
• Field of Search: 424/489, 424/490, 424/494
• US Class Current: 424/490
• CPC Class Codes: A61K 9/1652 Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin homeopathic globules A61K9/1623
• CPC Class Codes: A61K 9/1658 Proteins, e.g. albumin, gelatin

Abstract

A pharmaceutical composition in the form of beads prepared by an extrusion-spheronization technique and containing more than 80% by weight drug, less than 15% by weight non-lipophilic binder-plasticizer, such as microcrystalline cellulose to achieve required plasticity for processing, a starch-based excipient such as sodium starch glycolate or pregelatinized starch to control water/fluid distribution and thereby inhibit agglomeration during processing, and water-soluble binder such as hydrolyzed gelatin to make the final beads less friable. During processing a granulating agent such as ethanol/water is added to improve blend properties and control during spheronization. A method for preparing the above beads is also provided.

Claims

1. A method for preparing a pharmaceutical composition in the form of a bead having a diameter of 0.5 to 1.5 mm and containing more than about 80% by weight medicament, which comprises forming a wet mass of medicament, non-lipophilic binder-plasticizer which is a microcrystalline cellulose in an amount within the range of from about 1 to about 15% by weight of the final composition, starch-based excipient in an amount within the range of from about 0.5 to about 12% by weight of the final composition, wherein the starch-based excipient is sodium starch glycolate, corn starch, croscarmellose, pregelatinized starch or mixtures thereof, and optionally water-soluble binder with a granulating fluid, extruding said wet mass to form an extrudate and forming said extrudate into beads and drying said beads.

2. A pharmaceutical composition in the form of a bead containing a high medicament load, comprising a medicament in an amount of more than about 80% by weight of the composition, a non-lipophilic binder-plasticizer which is microcrystalline cellulose in an amount within the range of from 1 to about 15% by weight of said composition, a starch-based excipient in an amount within the range of from about 0.5 to about 12% by weight of said composition, wherein the starch-based excipient is sodium starch glycolate, corn starch, croscarmellose, pregelatinized starch or mixtures thereof, and optionally a water-soluble binder, prepared by the process as defined in claim 1.

3. The composition as defined in claim 2 wherein said non-lipophilic binder-plasticizer is present in an amount within the range of from about 2 to about 12% by weight of the composition.

4. The composition as defined in claim 2 wherein the starch-based excipient is present in an amount within the range of from about 1 to about 10% by weight of the composition.

5. The composition as defined in claim 2 wherein the water-soluble binder is present in an amount within the range of from about 0.2 to about 5% by weight of the composition.

6. The composition as defined in claim 2 wherein the starch-based excipient is sodium starch glycolate, croscarmellose, pregelatinized starch, or mixtures thereof.

7. The composition as defined in claim 2 wherein said medicament is an angiotensin-converting enzyme (ACE) inhibitor.

8. The composition as defined in claim 7 wherein said ACE inhibitor is selected from the group consisting of a substituted proline derivative, an ether or thioether mercaptoacyl proline, a carboxyalkyl dipeptide derivative, a phosphinylalkanoyl proline derivative, a phosphonamidate derivative, a phosphonate derivative and a prolylamino acid derivative.

9. The composition as defined in claim 7 wherein said ACE inhibitor is captopril.

10. The composition as defined in claim 8 wherein said ACE inhibitor is zofenopril or fosinopril.

11. The composition as defined in claim 8 wherein said ACE inhibitor is enalapril.

12. The composition as defined in claim 2 wherein the medicament is erythromycin.

13. The composition as defined in claim 2 wherein said medicament is captopril or erythromycin, said binder-plasticizer is microcrystalline cellulose, said starch-based excipient is sodium starch glycolate or pregelatinized starch and said water-soluble binder is hydrolyzed gelatin.

14. The composition as defined in claim 2 including a film-coating on said beads.

15. The composition as defined in claim 2 wherein said medicament is present in an amount within the range of from about 80 to about 95% by weight of said composition.

16. The method as defined in claim 1 wherein said medicament is an ACE inhibitor.

17. The method as defined in claim 1 wherein said binder-plasticizer is microcrystalline cellulose, and starch-based excipient is sodium starch glycolate, and said water-soluble binder is hydrolyzed gelatin.

18. The method as defined in claim 1 wherein said granulating fluid is an ethanol/water solution.

19. The method as defined in claim 1 further including the step of applying a film coating on the dried beads.